Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 22Head & Neck 16Thoracic 10Tumor-Agnostic 3Other solid neoplasm 2CNS 2Breast 2Sarcoma 1Myeloid 1Lymphoid 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Solid Tumors 1Advanced Solid Tumors 1

Interventions

pembrolizumab 15Injections 13Pemetrexed 8Carboplatin 8tislelizumab 6Interviews as Topic 6Standard of Care 5Specimen Handling 5Practice Guidelines as Topic 5Fluorouracil 5Cisplatin 5Bevacizumab 5atezolizumab 4Oxaliplatin 4Docetaxel 4sotorasib 3fludarabine 3Paclitaxel 3Nivolumab 3Methods 3Leucovorin 3Irinotecan 3Educational Status 3Early Intervention, Educational 3Capecitabine 3toripalimab 2Radiotherapy, Intensity-Modulated 2Patient Navigation 2Magnetic Resonance Spectroscopy 2Gemcitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Cetuximab × Other solid neoplasm × 30 days × Clear all
NCT05067283 2026-05-26

KANDLELIT-001

Merck Sharp & Dohme LLC

Phase 1 Recruiting
830 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT07415031 2026-05-15

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Mirati Therapeutics Inc.

Phase 2 Recruiting
170 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡